NCT01828034View on ClinicalTrials.gov

First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

May 30, 2019

Study Completion Date

May 30, 2019

Conditions

Advanced Biliary Tract Carcinoma

Interventions

DRUG

Gemcitabine

DRUG

Cisplatin

DRUG

MEK162

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Array BioPharma

All Listed Sponsors

collaborator

Array BioPharma

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER